Tuesday, November 28, 2017 9:09:41 PM
I really don’t care when the trial starts. It seems I’ve become more patient and I would recommend others to do the same.
If you sell, you will regret it. We have unprecedented results up to 2 years. And safety to boot.
Anavex has stated that our sample size allows for reliable and meaningful predictions for larger populations.
Ariana has analyzed the crap out of our data and has come up with 83 rules from over 71,000 relations.
We know higher concentration and earlier equals better. Only 2 clear rules so far. Others will be narrowed down and simplified.
Don’t forget RWE and all of the other preclinical data that says our drug does something good.
Now we get to PICK who is in our trial! How is that even possible. I feel like the teacher just told me I could cheat on my test using any and all the resources you could get your hands on. Too funny!!
And we are quibbling over a start date that isn’t even late yet. And if it is. SO WHAT!! They are letting us see the flop, the turn and the river cards before we decide if we want to go all in. Not only that, we get to pick what those cards are.
Taking candy from a baby!!
If you sell, you will regret it. We have unprecedented results up to 2 years. And safety to boot.
Anavex has stated that our sample size allows for reliable and meaningful predictions for larger populations.
Ariana has analyzed the crap out of our data and has come up with 83 rules from over 71,000 relations.
We know higher concentration and earlier equals better. Only 2 clear rules so far. Others will be narrowed down and simplified.
Don’t forget RWE and all of the other preclinical data that says our drug does something good.
Now we get to PICK who is in our trial! How is that even possible. I feel like the teacher just told me I could cheat on my test using any and all the resources you could get your hands on. Too funny!!
And we are quibbling over a start date that isn’t even late yet. And if it is. SO WHAT!! They are letting us see the flop, the turn and the river cards before we decide if we want to go all in. Not only that, we get to pick what those cards are.
Taking candy from a baby!!
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
